
BBIO Stock Forecast & Price Target
BBIO Analyst Ratings
Bulls say
BridgeBio Pharma is poised for growth and potential success in the rare disease market with a strong pipeline and potential for significant peak sales. However, they face financial risks due to limited cash reserves and high debt, and the success of the company will depend on obtaining regulatory approval and successfully commercializing their products in the highly competitive biotechnology industry.
Bears say
BridgeBio Pharma is in the process of advancing multiple clinical programs, but the company has a significant amount of debt and requires a considerable amount of funding to continue developing its pipeline. Additionally, the company faces competition from existing treatments in the market, which limits its potential for market penetration. There is also financial risk, as the company must generate enough cash flow to service its debt and may not have sufficient resources if its programs are not successful.
This aggregate rating is based on analysts' research of BridgeBio Pharma Inc and is not a guaranteed prediction by Public.com or investment advice.
BBIO Analyst Forecast & Price Prediction
Start investing in BBIO
Order type
Buy in
Order amount
Est. shares
0 shares